AVDL - Avadel Pharmaceuticals plc

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
2.3300
+0.1600 (+7.37%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Previous Close2.1700
Open2.1500
Bid2.1000 x 800
Ask3.0000 x 1000
Day's Range2.1500 - 2.3900
52 Week Range1.0300 - 5.2500
Volume347,038
Avg. Volume302,982
Market Cap87.259M
Beta (3Y Monthly)1.34
PE Ratio (TTM)N/A
EPS (TTM)-2.7240
Earnings DateNov 4, 2019 - Nov 8, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.50
Trade prices are not sourced from all markets
  • Jazz (JAZZ) Acquires Cavion, Adds Movement Disorder Candidate
    Zacks

    Jazz (JAZZ) Acquires Cavion, Adds Movement Disorder Candidate

    Jazz (JAZZ) acquires privately-held Cavion for a total consideration of $312.5 million including an upfront payment of $52.5 million and $260 million in potential clinical, regulatory and commercial milestones.

  • GlobeNewswire

    Avadel Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Company Update

    Better-than-expected Hospital Product revenue improves liquidity position Restructuring and other cost reduction actions on track to realize $80 to $90 million in annualized.

  • GlobeNewswire

    Avadel Pharmaceuticals Receives New PDUFA Date for AV001 of December 15, 2019

    Avadel Pharmaceuticals plc (AVDL), a company focused on developing FT218 for narcolepsy, today announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) Action Date relating to the New Drug Application (NDA) for AV001, a sterile injectable product designed for use in the hospital setting, by three months to December 15, 2019.  The NDA for AV001 was originally accepted in May 2019 under the FDA’s Priority Review program with a statutory six-month review. This three-month extension relates to recent submissions Avadel made in response to FDA requests for additional analytical information. The FDA determined that these submissions constitute a major amendment and will require additional time to review.

  • GlobeNewswire

    Avadel Pharmaceuticals Further Strengthens Clinical and Medical Team

    DUBLIN, Ireland, Aug. 01, 2019 -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218 for narcolepsy, today announced the appointments of Courtney.

  • GlobeNewswire

    Avadel Pharmaceuticals to Report Second Quarter 2019 Financial Results

    DUBLIN, Ireland, July 29, 2019 -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218 for narcolepsy, today announced that it will host a.

  • Do Directors Own Avadel Pharmaceuticals plc (NASDAQ:AVDL) Shares?
    Simply Wall St.

    Do Directors Own Avadel Pharmaceuticals plc (NASDAQ:AVDL) Shares?

    A look at the shareholders of Avadel Pharmaceuticals plc (NASDAQ:AVDL) can tell us which group is most powerful...

  • Jazz (JAZZ) Acquires Early-Stage Precision Oncology Asset
    Zacks

    Jazz (JAZZ) Acquires Early-Stage Precision Oncology Asset

    Jazz (JAZZ) acquired Redx Pharma's early stage pan-RAF inhibitor program for developing potential treatment for cancer with RAF and RAS mutations.

  • Jazz's (JAZZ) New Sleep Drug Sunosi Gets Schedule IV Status
    Zacks

    Jazz's (JAZZ) New Sleep Drug Sunosi Gets Schedule IV Status

    Jazz Pharmaceuticals' (JAZZ) recently approved sleep drug, Sunosi, receives schedule IV designation under controlled substance list from the Drug Enforcement Agency.

  • GlobeNewswire

    Avadel to Present New Data on Once-Nightly Sodium Oxybate at SLEEP 2019 Conference

    Avadel Pharmaceuticals plc (AVDL), a company focused on developing FT218 for narcolepsy, today announced it will present two posters at the 33rd Annual Meeting of the Associated Professional Sleep Societies being held in San Antonio, Texas, from June 8-12, 2019. “Our once-nightly controlled-release sodium oxybate demonstrated lower overall peak plasma concentrations (Cmax) and similar total exposures (AUC), compared to twice-nightly sodium oxybate in a head-to-head study,” said Jordan Dubow, MD, Chief Medical Officer of Avadel Pharmaceuticals.

  • GlobeNewswire

    Avadel Pharmaceuticals Appoints Gregory J. Divis Chief Executive Officer

    Avadel Pharmaceuticals plc (AVDL), a company focused on developing FT218 for narcolepsy, today announced the appointment of Gregory J. Divis as Chief Executive Officer and member of the Board of Directors. “Since being named Interim CEO at the beginning of 2019, Greg has done an excellent job leading the Company through rapid restructuring while directing our focus toward the successful development of FT218, our novel once-nightly therapy for narcolepsy patients,” said Geoffrey Glass, Chairman of Avadel’s Board of Directors.

  • GlobeNewswire

    Avadel Pharmaceuticals Announces FDA Acceptance of New Drug Application for AV001

    DUBLIN, Ireland, May 22, 2019 (GLOBE NEWSWIRE) --  Avadel Pharmaceuticals plc (AVDL), today announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA) for the Company’s fourth Hospital Product, AV001. It has been granted Priority Review status by the FDA resulting in a six-month review period. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) target action date of September 15, 2019.

  • Introducing Avadel Pharmaceuticals (NASDAQ:AVDL), The Stock That Tanked 82%
    Simply Wall St.

    Introducing Avadel Pharmaceuticals (NASDAQ:AVDL), The Stock That Tanked 82%

    Want to participate in a short research study? Help shape the future of investing tools and you could win a $250 gift card! Even the best investor on earth makes unsuccessful investments. But it would be foolish to simply...

  • Associated Press

    Avadel: 1Q Earnings Snapshot

    The Dublin-based company said it had a loss of 35 cents per share. The specialty pharmaceutical company posted revenue of $16.4 million in the period. The company's shares closed at $1.20. A year ago, ...

  • GlobeNewswire

    Avadel Pharmaceuticals Reports First Quarter 2019 Financial Results

    REST-ON 63% enrolled; 98 patients remain to be enrolled Jordon Dubow, M.D., appointed as Chief Medical Officer Noctiva™-related assets sold; all operational activities have.

  • ACCESSWIRE

    Avadel Pharmaceuticals Plc to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / May 8, 2019 / Avadel Pharmaceuticals Plc (NASDAQ: AVDL ) will be discussing their earnings results in their 2019 First Quarter Earnings to be held on May 8, 2019 at 8:30 AM ...

  • GlobeNewswire

    Avadel Pharmaceuticals to Report First Quarter 2019 Financial Results

    DUBLIN, Ireland, April 29, 2019 -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218 for sleep disorders, today announced that it will host a.

  • GlobeNewswire

    Avadel Pharmaceuticals Announces Appointment of Jordan Dubow, M.D., as Chief Medical Officer

    Avadel Pharmaceuticals plc (AVDL), a company focused on developing FT218 for sleep disorders, today announced that it has appointed Jordan Dubow, M.D., as Chief Medical Officer. Dr. Dubow brings extensive experience leading clinical development programs in sleep and neurological disorders to Avadel, where he will lead the development of FT218 for the treatment of excessive daytime sleepiness and cataplexy in patients suffering from narcolepsy. “Dr. Dubow’s experience in a wide range of neurological disorders, especially sleep, will be invaluable to Avadel as we continue advancing FT218 toward approval and commercialization,” said Geoff Glass, Chairman of Avadel Pharmaceuticals.

  • Jazz's Xyrem Follow-On Drug Succeeds in Phase III Study
    Zacks

    Jazz's Xyrem Follow-On Drug Succeeds in Phase III Study

    Jazz Pharmaceuticals (JAZZ) announced positive top-line data from its phase III study on low sodium formulation of Xyrem, JZP-258.

  • Jazz Pharmaceuticals' Sleep Drug NDA Awaits FDA Decision
    Zacks

    Jazz Pharmaceuticals' Sleep Drug NDA Awaits FDA Decision

    The FDA will provide its decision on Jazz's (JAZZ) candidate, solriamfetol, for excessive daytime sleepiness with narcolepsy on Wednesday.

  • Associated Press

    Avadel: 4Q Earnings Snapshot

    The Dublin-based company said it had a loss of $1.72 per share. The specialty pharmaceutical company posted revenue of $20.9 million in the period. For the year, the company reported a loss of $95.3 million, ...

  • GlobeNewswire

    Avadel Pharmaceuticals Reports Fourth Quarter and Full Year 2018 Financial Results

    DUBLIN, Ireland, March 15, 2019 -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on developing FT218 for sleep disorders, today announced its financial results.

  • GlobeNewswire

    Avadel Pharmaceuticals to Report Fourth Quarter and Full Year 2018 Financial Results

    Avadel Pharmaceuticals plc (AVDL), a company focused on developing FT218 for sleep disorders, today announced that it will host a conference call and live webcast discussion at 8:30 a.m. EDT on Friday, March 15, 2019, to provide a corporate update and discuss details of the Company's financial results for the quarter and year ended December 31, 2018. A live audio webcast can be accessed by visiting the investor relations section of the Company’s website, www.avadel.com. Avadel Pharmaceuticals plc (AVDL) is a branded specialty pharmaceutical company.  Our primarily focus is on the development and potential FDA approval for FT218 which is in a Phase III clinical trial for the treatment of narcolepsy patients suffering from excessive daytime sleepiness (EDS) and cataplexy.  In addition, we market three sterile injectable drugs used in the hospital setting which were developed under our “unapproved marketed drug” (UMD) program.  The Company is headquartered in Dublin, Ireland with operations in St. Louis, Missouri and Lyon, France.

  • GlobeNewswire

    Avadel Pharmaceuticals Clarifies Announcement of Corporate Restructuring

    Avadel Pharmaceuticals plc (AVDL) provided clarification regarding the restructuring actions announced earlier today. The restructuring actions do not trigger a default or violate covenants related to the 4.50% Exchangeable Senior Notes due in 2023.

  • GlobeNewswire

    Avadel Pharmaceuticals Announces Restructuring to Focus on FT218 Clinical Development Program

    Avadel Pharmaceuticals plc (AVDL), today announced a corporate restructuring to assure the financial health required to maximize the value of FT218, currently in Phase III development for the treatment of excessive daytime sleepiness (EDS) and Cataplexy in patients suffering from Narcolepsy. Avadel expects to realize $70 to $75 million in cost reductions in 2019 as compared to 2018 as a result of the restructuring plan, driven primarily by exiting NOCTIVA™. “It is clear that FT218, an investigational, once-nightly formulation of sodium oxybate, is the Company’s most promising and commercially-attractive asset targeting a large orphan market with an estimated value of nearly $1.5 billion in 2018,” said Greg Divis, interim Chief Executive Officer of Avadel.